Cindy L. O’Bryant

2.8k total citations · 1 hit paper
68 papers, 2.1k citations indexed

About

Cindy L. O’Bryant is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cindy L. O’Bryant has authored 68 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cindy L. O’Bryant's work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Cindy L. O’Bryant is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Cindy L. O’Bryant collaborates with scholars based in United States, Canada and United Kingdom. Cindy L. O’Bryant's co-authors include Lia Gore, D. Ross Camidge, Laura Q.M. Chow, Sami Diab, Bonnie Ky, Robert L. Page, Davy Cheng, Robin J. Trupp, C. Michael Stein and Anne P. Spencer and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Cindy L. O’Bryant

67 papers receiving 2.0k citations

Hit Papers

Drugs That May Cause or E... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Drugs That May Cause or Exacerbate Heart Failure
    2016 324 citations Cindy L. O’Bryant et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cindy L. O’Bryant United States 23 917 738 471 220 205 68 2.1k
Antonella Brunello Italy 23 354 0.4× 907 1.2× 474 1.0× 252 1.1× 143 0.7× 119 1.8k
Laura Cortesi Italy 28 753 0.8× 1.0k 1.4× 343 0.7× 712 3.2× 180 0.9× 172 2.9k
Wilson I. Gonsalves United States 33 2.0k 2.2× 1.2k 1.6× 188 0.4× 228 1.0× 104 0.5× 236 3.4k
Catherine C. Lerro United States 8 758 0.8× 1.3k 1.8× 698 1.5× 474 2.2× 128 0.6× 18 2.9k
Massimo Breccia Italy 38 1.7k 1.8× 942 1.3× 303 0.6× 152 0.7× 176 0.9× 403 5.6k
Keun Sang Kwon South Korea 23 618 0.7× 563 0.8× 632 1.3× 190 0.9× 55 0.3× 51 1.9k
Sigbjørn Smeland Norway 32 637 0.7× 858 1.2× 1.4k 3.0× 298 1.4× 225 1.1× 105 2.9k
Albert G. Frauman Australia 28 519 0.6× 278 0.4× 387 0.8× 201 0.9× 461 2.2× 68 2.4k
Maartje Los Netherlands 26 320 0.3× 996 1.3× 746 1.6× 298 1.4× 87 0.4× 80 2.0k
Francesco Ferraù Italy 28 421 0.5× 929 1.3× 554 1.2× 298 1.4× 76 0.4× 148 2.8k

Countries citing papers authored by Cindy L. O’Bryant

Since Specialization
Citations

This map shows the geographic impact of Cindy L. O’Bryant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cindy L. O’Bryant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cindy L. O’Bryant more than expected).

Fields of papers citing papers by Cindy L. O’Bryant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cindy L. O’Bryant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cindy L. O’Bryant. The network helps show where Cindy L. O’Bryant may publish in the future.

Co-authorship network of co-authors of Cindy L. O’Bryant

This figure shows the co-authorship network connecting the top 25 collaborators of Cindy L. O’Bryant. A scholar is included among the top collaborators of Cindy L. O’Bryant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cindy L. O’Bryant. Cindy L. O’Bryant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, Claire, Roberto Sommavilla, Cindy L. O’Bryant, et al.. (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(2). 223–235. 1 indexed citations
2.
Davis, S. Lindsey, Wells A. Messersmith, W. Thomas Purcell, et al.. (2024). A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors. Cancers. 16(8). 1456–1456.
3.
Ghimire, Anukul, Wen Xia, Cathleen Doherty, et al.. (2024). Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs. The Journal of Clinical Pharmacology. 65(6). 763–778. 1 indexed citations
4.
Akce, Mehmet, Anthony B. El-Khoueiry, Sarina A. Piha‐Paul, et al.. (2021). Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemotherapy and Pharmacology. 88(5). 825–836. 11 indexed citations
5.
Glode, Ashley E., et al.. (2020). Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. Journal of Oncology Pharmacy Practice. 26(6). 1369–1373. 3 indexed citations
6.
O’Bryant, Cindy L., Melanie S. Joy, Susan L. Hogan, et al.. (2020). Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. UNC Libraries. 1 indexed citations
7.
Ibrahim, Mustafa E., Yichun Hu, Susan L. Hogan, et al.. (2018). Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. European Journal of Clinical Pharmacology. 75(1). 51–57. 29 indexed citations
8.
O’Bryant, Cindy L., et al.. (2017). Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor‐Resistant Basal Cell Carcinoma Cells via Targeting EGFR‐MAPK‐Akt and Hedgehog Signaling. Photochemistry and Photobiology. 93(4). 999–1007. 24 indexed citations
9.
Hu, Yichun, Susan L. Hogan, Cindy L. O’Bryant, et al.. (2017). Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. International Journal of Molecular Sciences. 18(7). 1333–1333. 27 indexed citations
10.
Wong, Kit Man, Sinéad Noonan, Cindy L. O’Bryant, & Antonio Jimeno. (2015). Alectinib for the treatment of ALK-positive stage IV non-small celllung cancer. Drugs of today. 51(3). 161–161. 5 indexed citations
11.
Hong, David S., Daniel W. Bowles, Gerald S. Falchook, et al.. (2012). A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(15). 4173–4182. 134 indexed citations
12.
Lam, Elaine T., S. Gail Eckhardt, Wells A. Messersmith, et al.. (2011). Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). C18–C18. 2 indexed citations
13.
Bowles, Daniel W., Cindy L. O’Bryant, D. Ross Camidge, & Antonio Jimeno. (2011). The intersection between cannabis and cancer in the United States. Critical Reviews in Oncology/Hematology. 83(1). 1–10. 52 indexed citations
14.
O’Bryant, Cindy L., Sunny A. Linnebur, Traci E. Yamashita, & Jean S. Kutner. (2008). Inconsistencies in Opioid Equianalgesic Ratios: Clinical and Research Implications. Journal of Pain & Palliative Care Pharmacotherapy. 22(4). 282–290. 19 indexed citations
15.
O’Bryant, Cindy L., et al.. (2008). Community pharmacists' knowledge of and attitudes toward oral chemotherapy. Journal of the American Pharmacists Association. 48(5). 632–639. 29 indexed citations
16.
Lam, Elaine T., Cindy L. O’Bryant, M. Basche, et al.. (2008). A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular Cancer Therapeutics. 7(12). 3685–3694. 6 indexed citations
17.
Chow, Laura Q.M., Sabine Eckhardt, Cindy L. O’Bryant, et al.. (2007). A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 62(4). 631–646. 22 indexed citations
18.
O’Bryant, Cindy L., Stephen Leong, D. Ross Camidge, et al.. (2007). A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma. Molecular Cancer Therapeutics. 6. 3 indexed citations
19.
O’Bryant, Cindy L., S. Hariharan, Siew Hong Leong, et al.. (2006). 412 POSTER An open-label study to characterize the pharmacokinetic (pk) parameters of erlotinib in patients with advanced solid tumors with adequate or moderately imparied hepatic function. European Journal of Cancer Supplements. 4(12). 126–127. 1 indexed citations
20.
Cohen, Robert, D. Ross Camidge, Sami Diab, et al.. (2006). 647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. European Journal of Cancer Supplements. 4(12). 195–195. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonella Brunello Breakdown of academic impact, for papers by Laura Cortesi Breakdown of academic impact, for papers by Wilson I. Gonsalves Breakdown of academic impact, for papers by Catherine C. Lerro Breakdown of academic impact, for papers by Massimo Breccia Breakdown of academic impact, for papers by Keun Sang Kwon Breakdown of academic impact, for papers by Sigbjørn Smeland Breakdown of academic impact, for papers by Albert G. Frauman Breakdown of academic impact, for papers by Maartje Los Breakdown of academic impact, for papers by Francesco Ferraù
Rankless by CCL
2026